应交易所要求,美/港股行情延时15分钟展示,下载APP即可免费查看实时行情。
关闭
01952 云顶新耀-B
耶稣受难节休市 03-28 16:08:03
23.500
+1.600
+7.31%
最高
24.150
最低
22.100
成交量
661.60万
今开
22.550
昨收
21.900
日振幅
9.36%
总市值
76.14亿
流通市值
76.14亿
总股本
3.24亿
成交额
1.54亿
换手率
2.04%
流通股本
3.24亿
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
北京优虎网络科技有限公司
免责声明:香港交易所资讯服务有限公司、其控股公司及/或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度,但不能保证其绝对准确和可靠,且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任(不管是否侵权法下的责任或合约责任又或其它责任)
资讯
新帖
简况
去年亏损扩大至8.4亿元,云顶新耀扭亏难题待解,两款明星药冲击7亿销售目标
时代周报 · 17:20
去年亏损扩大至8.4亿元,云顶新耀扭亏难题待解,两款明星药冲击7亿销售目标
云顶新耀:商业化迈入关键一年,耐赋康?销售预期达4-5亿元
和讯网 · 09:17
云顶新耀:商业化迈入关键一年,耐赋康?销售预期达4-5亿元
云顶新耀2023年报:商业化初露锋芒 发力自研mRNA治疗性疫苗
证券时报·e公司 · 03-28 14:26
云顶新耀2023年报:商业化初露锋芒 发力自研mRNA治疗性疫苗
云顶新耀-B(01952)股价上升8.219%,现价港币$23.7
阿斯达克财经 · 03-28 10:49
云顶新耀-B(01952)股价上升8.219%,现价港币$23.7
港股异动 | 云顶新耀-B(01952)绩后涨超5% 全年营收增近9倍 多位高管宣布自愿禁售
智通财经 · 03-28 10:30
港股异动 | 云顶新耀-B(01952)绩后涨超5% 全年营收增近9倍 多位高管宣布自愿禁售
《公司业绩》云顶新耀-B(01952.HK)全年亏损扩至8.44亿人币
阿斯达克财经 · 03-28 10:09
《公司业绩》云顶新耀-B(01952.HK)全年亏损扩至8.44亿人币
云顶新耀-B(01952.HK):2023年收益达1.26亿元
格隆汇资讯 · 03-28 09:14
云顶新耀-B(01952.HK):2023年收益达1.26亿元
云顶新耀-B公布2023年业绩 实现收入1.26亿元同比增长884%
新浪港股 · 03-28 08:16
云顶新耀-B公布2023年业绩 实现收入1.26亿元同比增长884%
云顶新耀-B(01952)公布2023年业绩 实现收入1.26亿元 同比增长884%
智通财经 · 03-28 07:24
云顶新耀-B(01952)公布2023年业绩 实现收入1.26亿元 同比增长884%
云顶新耀-B:2023年经调整亏损7.136亿元,同比增亏
界面 · 03-28 07:24
云顶新耀-B:2023年经调整亏损7.136亿元,同比增亏
云顶新耀发布2023年度全年业绩
美通社 · 03-28 07:18
云顶新耀发布2023年度全年业绩
云顶新耀-B03月27日主力资金流出20万元 连续3日减仓
自选股智能写手 · 03-27 16:15
云顶新耀-B03月27日主力资金流出20万元 连续3日减仓
云顶新耀-B(01952)下跌5.12%,报23.15元/股
金融界 · 03-25
云顶新耀-B(01952)下跌5.12%,报23.15元/股
云顶新耀-B(01952)上涨5.52%,报26.75元/股
金融界 · 03-21
云顶新耀-B(01952)上涨5.52%,报26.75元/股
云顶新耀-B(01952)股价上升5.128%,现价港币$26.65
阿斯达克财经 · 03-21
云顶新耀-B(01952)股价上升5.128%,现价港币$26.65
云顶新耀宣布新加坡卫生科学局批准耐赋康®用于治疗成人原发性IgA肾病的新药上市许可申请
美通社 · 03-20
云顶新耀宣布新加坡卫生科学局批准耐赋康®用于治疗成人原发性IgA肾病的新药上市许可申请
云顶新耀(01952.HK)任命首席医学官及首席产品官
阿斯达克财经 · 03-19
云顶新耀(01952.HK)任命首席医学官及首席产品官
云顶新耀股东高管承诺半年不售股份 展现发展信心
和讯网 · 03-18
云顶新耀股东高管承诺半年不售股份 展现发展信心
加载更多
公司概况
公司名称:
云顶新耀-B
所属市场:
SEHK
上市日期:
--
主营业务:
云顶新耀有限公司是一家主要从事疗法的特许、临床开发及商业化业务,以解决尚未满足的医疗需求。该公司一直专注于创新候选药物的研发。该公司已开发极具前景的临床阶段候选药物产品组合,覆盖肿瘤、免疫学、心肾疾病及感染性疾病。该公司主要在大中华及亚太区其他新兴市场提供产品与服务。
发行价格:
--
{"stockData":{"symbol":"01952","market":"HK","secType":"STK","nameCN":"云顶新耀-B","latestPrice":23.5,"timestamp":1711613283015,"preClose":21.9,"halted":0,"volume":6616000,"delay":0,"floatShares":323983170,"shares":323983170,"eps":-0.8962596,"marketStatus":"耶稣受难节休市","marketStatusCode":7,"change":1.6,"latestTime":"03-28 16:08:03","open":22.55,"high":24.15,"low":22.1,"amount":154207150,"amplitude":0.093607,"askPrice":23.55,"askSize":500,"bidPrice":23.5,"bidSize":58500,"shortable":3,"etf":0,"ttmEps":-0.010232012873185427,"exchange":"SEHK","tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1712021400000},"adr":0,"listingDate":1602172800000,"adjPreClose":21.9,"openAndCloseTimeList":[[1711589400000,1711598400000],[1711602000000,1711612800000]],"volumeRatio":1.1146411450404412,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/01952","defaultTab":"news","newsList":[{"id":"2423458641","title":"去年亏损扩大至8.4亿元,云顶新耀扭亏难题待解,两款明星药冲击7亿销售目标","url":"https://stock-news.laohu8.com/highlight/detail?id=2423458641","media":"时代周报","top":-1,"share":"https://www.laohu8.com/m/news/2423458641?lang=zh_cn&edition=full","pubTime":"2024-03-29 17:20","pubTimestamp":1711704044,"startTime":"0","endTime":"0","summary":"不过,云顶新耀全年亏损却进一步增大。年报显示,年内亏损净额由2022年的2.473亿元增至2023年的8.445亿元。经调整Trodelvy交易的一次性收益,云顶新耀年内净亏损较2022年的15.696亿元减少7.251亿元。另外,期间研发费用亦同比减少2.70亿元。截至2023年年末,云顶新耀现金及现金等价物以及银行存款为23.50亿元。据云顶新耀透露,2023年,依嘉录得销售收入约0.99亿元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024032917213487c4bd47&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024032917213487c4bd47&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2423105311","title":"云顶新耀:商业化迈入关键一年,耐赋康?销售预期达4-5亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2423105311","media":"和讯网","top":-1,"share":"https://www.laohu8.com/m/news/2423105311?lang=zh_cn&edition=full","pubTime":"2024-03-29 09:17","pubTimestamp":1711675050,"startTime":"0","endTime":"0","summary":"云顶新耀在2025年底前计划实现现金收支平衡,进入商业化关键一年。的销售收入合计可达7亿元。被认为是公司最为看重的产品之一,预期今年的销售收入可以达到4亿-5亿元。云顶新耀已经建立起了约200人的商业化团队,并计划逐步组建一支约120人的肾科销售团队。为了降低运营成本,云顶新耀在2023年进行了降本增效工作,整体运营成本减少4.76亿元,同比下降33.7%,经调整后的净亏损大幅收窄。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202403290947568b6ffa92&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202403290947568b6ffa92&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2422330821","title":"云顶新耀2023年报:商业化初露锋芒 发力自研mRNA治疗性疫苗","url":"https://stock-news.laohu8.com/highlight/detail?id=2422330821","media":"证券时报·e公司","top":-1,"share":"https://www.laohu8.com/m/news/2422330821?lang=zh_cn&edition=full","pubTime":"2024-03-28 14:26","pubTimestamp":1711607175,"startTime":"0","endTime":"0","summary":"3月27日晚,港股创新药企云顶新耀交出了商业化后的首份成绩单。财报显示,2023年云顶新耀实现总收入为1.26亿元,同比增长884%,高于之前7000万至人民币1亿元的业绩指引。与此同时,得益于采用聚焦、高效、精干的商业化模式及精细化管理,2023年公司运营成本大幅减少4.76亿元,同比下降33.7%,经调整后的净亏损大幅收窄6.26亿元,同比下降46.7%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202403283027810447.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2422907212","title":"云顶新耀-B(01952)股价上升8.219%,现价港币$23.7","url":"https://stock-news.laohu8.com/highlight/detail?id=2422907212","media":"阿斯达克财经","top":-1,"share":"https://www.laohu8.com/m/news/2422907212?lang=zh_cn&edition=full","pubTime":"2024-03-28 10:49","pubTimestamp":1711594140,"startTime":"0","endTime":"0","summary":"[上升股]云顶新耀-B(01952) 股价在上午10:49比前收市价上升8.219%,现股价为港币$23.7。至目前为止,今日最高价为$23.7,而最低价为$22.1。总成交量为312.2万股,总成交金额为港币$7.132千万。","market":"sh","thumbnail":"http://plib.aastocks.com/aafnnews/image/medialib/20190515141040914_s.png","type":0,"news_type":0,"thumbnails":["http://plib.aastocks.com/aafnnews/image/medialib/20190515141040914_s.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAR2403281547/aamm-all-category","is_publish_highlight":false,"gpt_icon":0},{"id":"2422790289","title":"港股异动 | 云顶新耀-B(01952)绩后涨超5% 全年营收增近9倍 多位高管宣布自愿禁售","url":"https://stock-news.laohu8.com/highlight/detail?id=2422790289","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2422790289?lang=zh_cn&edition=full","pubTime":"2024-03-28 10:30","pubTimestamp":1711593056,"startTime":"0","endTime":"0","summary":"智通财经APP获悉,云顶新耀-B(01952)绩后涨超5%,截至发稿,涨5.02%,报23港元,成交额5839.51万港元。消息面上,云顶新耀公告,2023年收益1.259亿元,同比增长884%,主要由于依嘉于中国大陆及香港上市、耐赋康于澳门上市、依嘉在新加坡的销售增长及于过渡期内与吉利德科学公司在新加坡销售Trodelvy所致。值得注意的是,公司控股股东CBC集团、公司执行董事兼首席执行官罗永庆及公司执行董事兼首席财务官何颖已通知公司,彼等各自自愿承诺于未来至少六个月将不会出售其直接或间接拥有的公司任何股份,基于对公司未来前景及长远发展的坚定信心。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1094417.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2422090906","title":"《公司业绩》云顶新耀-B(01952.HK)全年亏损扩至8.44亿人币","url":"https://stock-news.laohu8.com/highlight/detail?id=2422090906","media":"阿斯达克财经","top":-1,"share":"https://www.laohu8.com/m/news/2422090906?lang=zh_cn&edition=full","pubTime":"2024-03-28 10:09","pubTimestamp":1711591740,"startTime":"0","endTime":"0","summary":"云顶新耀-B(01952.HK) 公布截至去年12月底止全年业绩,营业额1.26亿元人民币(下同),按年升884.5%。亏损扩大至8.44亿元,上年同期蚀2.47亿元;每股亏损2.7元。不派息。(jl/da)(港股报价延迟最少十五分钟。沽空资料截至 2024-03-27 16:25。)过往派息公布日期派息事项派息内容2023/08/24中期业绩无派息2023/03/31末期业绩无派息 2022/08/24中期业绩无派息 2022/03/29末期业绩无派息 AASTOCKS新闻","market":"sh","thumbnail":"http://plib.aastocks.com/aafnnews/image/medialib/20210311103606358_s.jpg","type":0,"news_type":0,"thumbnails":["http://plib.aastocks.com/aafnnews/image/medialib/20210311103606358_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1338133/latest-news/AAFN","is_publish_highlight":false,"gpt_icon":0},{"id":"2422093189","title":"云顶新耀-B(01952.HK):2023年收益达1.26亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2422093189","media":"格隆汇资讯","top":-1,"share":"https://www.laohu8.com/m/news/2422093189?lang=zh_cn&edition=full","pubTime":"2024-03-28 09:14","pubTimestamp":1711588473,"startTime":"0","endTime":"0","summary":"格隆汇3月28日丨云顶新耀-B发布公告,截至2023年12月31日止年度,收益由2022年度的人民币1280万元增加约884%至1.259亿元,主要由于依嘉于中国大陆及中国香港上市、耐赋康于中国澳门上市、依嘉在新加坡的销售增长及于过渡期内与吉利德科学公司在新加坡销售Trodelvy所致。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202403280949318b6b9804&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202403280949318b6b9804&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2422518974","title":"云顶新耀-B公布2023年业绩 实现收入1.26亿元同比增长884%","url":"https://stock-news.laohu8.com/highlight/detail?id=2422518974","media":"新浪港股","top":-1,"share":"https://www.laohu8.com/m/news/2422518974?lang=zh_cn&edition=full","pubTime":"2024-03-28 08:16","pubTimestamp":1711585014,"startTime":"0","endTime":"0","summary":"云顶新耀-B(01952)公布2023年业绩,收入为人民币1.26亿元,同比增长884%;研发开支约5.4亿元,同比收窄33.3%;亏损净额约8.445亿元。\n\n\n海量资讯、精准解读,尽在新浪财经APP","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"highlight_sina","url":"https://finance.sina.com.cn/stock/hkstock/ggscyd/2024-03-28/doc-inapvpiy3804036.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}","selectors":".art_box, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action, .fl_popup, .weibo_info","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/ggscyd/2024-03-28/doc-inapvpiy3804036.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2422855976","title":"云顶新耀-B(01952)公布2023年业绩 实现收入1.26亿元 同比增长884%","url":"https://stock-news.laohu8.com/highlight/detail?id=2422855976","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2422855976?lang=zh_cn&edition=full","pubTime":"2024-03-28 07:24","pubTimestamp":1711581899,"startTime":"0","endTime":"0","summary":"智通财经APP讯,云顶新耀-B 公布2023年业绩,收入为人民币1.26亿元,同比增长884%;研发开支约5.4亿元,同比收窄33.3%;亏损净额约8.445亿元。继耐赋康于2023 年底在澳门成功商业化上市后,公司计划于2024年在中国大陆、新加坡及中国香港上市这一重要创新产品,同时会在韩国及中国台湾寻求上市批准。耐赋康将于2024年上半年在中国大陆商业化上市,公司将逐步建立销售团队,预计到年底销售代表达到 120名,计划覆盖600家占据至少60%市场潜力的核心医院。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1094301.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2422750069","title":"云顶新耀-B:2023年经调整亏损7.136亿元,同比增亏","url":"https://stock-news.laohu8.com/highlight/detail?id=2422750069","media":"界面","top":-1,"share":"https://www.laohu8.com/m/news/2422750069?lang=zh_cn&edition=full","pubTime":"2024-03-28 07:24","pubTimestamp":1711581872,"startTime":"0","endTime":"0","summary":"云顶新耀-B3月28日在港交所公告,2023年收益1.259亿元,同比增长884%,主要由于依嘉®于中国大陆及香港上市、耐赋康®于澳门上市、依嘉®在新加坡的销售增长及于过渡期内与吉利德科学公司在新加坡销售Trodelvy®所致。2023年经调整亏损为7.136亿元,较2022年亏损增加6.962亿元。预计耐赋康®将于2024年在中国内地、香港及新加坡商业化上市。预计将于2024年在中国台湾及韩国获得耐赋康®新药上市许可批准。预计在2024年第3季度公布耐赋康®中国开放标签研究结果。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202403280724367a4f9494&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202403280724367a4f9494&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2422976806","title":"云顶新耀发布2023年度全年业绩","url":"https://stock-news.laohu8.com/highlight/detail?id=2422976806","media":"美通社","top":-1,"share":"https://www.laohu8.com/m/news/2422976806?lang=zh_cn&edition=full","pubTime":"2024-03-28 07:18","pubTimestamp":1711581480,"startTime":"0","endTime":"0","summary":"上海2024年3月28日 /美通社/ -- 云顶新耀,一家专注于创新药及疫苗研发、临床开发、制造及商业化的生物制药公司,今日公布2023年度全年财务业绩报告及业务进展。澳门于2023年8月受理本公司关于耐赋康的新药上市许可申请。于2023年11月,韩国食品医药品安全部受理耐赋康新药上市许可申请,用于治疗成年IgA肾病患者。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://wwwold.prnasia.com/story/archive/4372804_ZH72804_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2422959686","title":"云顶新耀-B03月27日主力资金流出20万元 连续3日减仓","url":"https://stock-news.laohu8.com/highlight/detail?id=2422959686","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2422959686?lang=zh_cn&edition=full","pubTime":"2024-03-27 16:15","pubTimestamp":1711527342,"startTime":"0","endTime":"0","summary":"03月27日, 云顶新耀-B股价涨1.62%,报收21.90元,成交金额1.14亿元,换手率1.59%,振幅9.05%,量比0.96。云顶新耀-B今日主力资金净流出20万元,连续3日净流出,上一交易日主力净流出390万元,今日环比减少94.87%。近一年数据显示,该股主力连续3日净流出后,次日下跌概率为50.00%,平均跌幅为3.71%。该股近5个交易日下跌13.41%,主力资金累计净流出641万元,其中1个交易日为股价上涨时净流出;近20日主力资金累计净流入6039万元,其中净流入天数为12日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202403271615548b68e35d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202403271615548b68e35d&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2422597155","title":"云顶新耀-B(01952)下跌5.12%,报23.15元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2422597155","media":"金融界","top":-1,"share":"https://www.laohu8.com/m/news/2422597155?lang=zh_cn&edition=full","pubTime":"2024-03-25 13:25","pubTimestamp":1711344356,"startTime":"0","endTime":"0","summary":"3月25日,云顶新耀-B(01952)盘中下跌5.12%,截至13:25,报23.15元/股,成交1.0亿元。云顶新耀有限公司是一家专注于后期临床阶段的生物制药公司,主要业务是在全球范围内引进专利许可,开发和商业化创新性疗法,以满足大中华区和其他新兴亚太市场的医疗需求。自2017年成立以来,公司已在肿瘤、免疫、心肾疾病和感染性疾病领域打造了8种临床阶段候选药物,以满足尚未满足的医疗需求,服务于大规模的潜在患者人群。截至2023年中报,云顶新耀-B营业总收入889.5万元、净利润-4.24亿元。3月27日,云顶新耀-B将披露2023财年年报。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://hk.jrj.com.cn/2024/03/25132539975372.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2421103951","title":"云顶新耀-B(01952)上涨5.52%,报26.75元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2421103951","media":"金融界","top":-1,"share":"https://www.laohu8.com/m/news/2421103951?lang=zh_cn&edition=full","pubTime":"2024-03-21 10:09","pubTimestamp":1710986999,"startTime":"0","endTime":"0","summary":"3月21日,云顶新耀-B(01952)盘中上涨5.52%,截至10:09,报26.75元/股,成交3293.82万元。云顶新耀有限公司是一家专注于后期临床阶段的生物制药公司,主要业务是在全球范围内引进专利许可,开发和商业化创新性疗法,以满足大中华区和其他新兴亚太市场的医疗需求。自2017年成立以来,公司已在肿瘤、免疫、心肾疾病和感染性疾病领域打造了8种临床阶段候选药物,以满足尚未满足的医疗需求,服务于大规模的潜在患者人群。截至2023年中报,云顶新耀-B营业总收入889.5万元、净利润-4.24亿元。3月27日,云顶新耀-B将披露2023财年年报。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://hk.jrj.com.cn/2024/03/21100939933440.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2421032704","title":"云顶新耀-B(01952)股价上升5.128%,现价港币$26.65","url":"https://stock-news.laohu8.com/highlight/detail?id=2421032704","media":"阿斯达克财经","top":-1,"share":"https://www.laohu8.com/m/news/2421032704?lang=zh_cn&edition=full","pubTime":"2024-03-21 10:09","pubTimestamp":1710986940,"startTime":"0","endTime":"0","summary":"[上升股]云顶新耀-B(01952) 股价在上午10:09比前收市价上升5.128%,现股价为港币$26.65。至目前为止,今日最高价为$26.65,而最低价为$25.5。总成交量为124.9万股,总成交金额为港币$3.248千万。","market":"fut","thumbnail":"http://plib.aastocks.com/aafnnews/image/medialib/20190212132919673_s.jpg","type":0,"news_type":0,"thumbnails":["http://plib.aastocks.com/aafnnews/image/medialib/20190212132919673_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAR2403212632/aamm-all-category","is_publish_highlight":false,"gpt_icon":0},{"id":"2420734297","title":"云顶新耀宣布新加坡卫生科学局批准耐赋康®用于治疗成人原发性IgA肾病的新药上市许可申请","url":"https://stock-news.laohu8.com/highlight/detail?id=2420734297","media":"美通社","top":-1,"share":"https://www.laohu8.com/m/news/2420734297?lang=zh_cn&edition=full","pubTime":"2024-03-20 09:00","pubTimestamp":1710896400,"startTime":"0","endTime":"0","summary":"上海2024年3月20日 /美通社/ -- 云顶新耀是一家专注于创新药及疫苗研发、临床开发、制造和商业化的生物制药公司,今日宣布新加坡卫生科学局已批准耐赋康用于治疗具有疾病进展风险的原发性IgA肾病成人患者。此次在新加坡获批,也即将造福东南亚地区急需对因治疗、延缓肾功能衰退的IgA 肾病患者。这项研究为期2年,包括9个月的耐赋康或安慰剂治疗期,随后是15个月的停药随访期。云顶新耀已打造多款疾病首创或者同类最佳的药物组合。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://wwwold.prnasia.com/story/archive/4366009_ZH66009_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2420666252","title":"云顶新耀(01952.HK)任命首席医学官及首席产品官","url":"https://stock-news.laohu8.com/highlight/detail?id=2420666252","media":"阿斯达克财经","top":-1,"share":"https://www.laohu8.com/m/news/2420666252?lang=zh_cn&edition=full","pubTime":"2024-03-19 09:18","pubTimestamp":1710811080,"startTime":"0","endTime":"0","summary":"云顶新耀(01952.HK) 宣布,任命曾庆雯为首席医学官及梁旭为首席产品官,以进一步加强管理团队,提升研发、临床开发、医学事务和市场营销部门之间的战略整合。曾庆雯将负责管理公司的临床开发团队,并通过跨部门合作开发自主研发及引进更多创新产品,同时领导新产品在中国的临床开发。而梁旭则会负责云顶新耀市场和医学事务部的战略和团队管理工作,与商业化团队密切合作,引领品牌战略和上市计划,确保营销策略的实施和执行。(gc/k)(港股报价延迟最少十五分钟。沽空资料截至 2024-03-18 16:25。)AASTOCKS新闻","market":"hk","thumbnail":"http://plib.aastocks.com/aafnnews/image/medialib/20210311103607146_s.jpg","type":0,"news_type":0,"thumbnails":["http://plib.aastocks.com/aafnnews/image/medialib/20210311103607146_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1334418/latest-news/AAFN","is_publish_highlight":false,"gpt_icon":0},{"id":"2420736428","title":"云顶新耀股东高管承诺半年不售股份 展现发展信心","url":"https://stock-news.laohu8.com/highlight/detail?id=2420736428","media":"和讯网","top":-1,"share":"https://www.laohu8.com/m/news/2420736428?lang=zh_cn&edition=full","pubTime":"2024-03-18 17:11","pubTimestamp":1710753069,"startTime":"0","endTime":"0","summary":"快讯正文云顶新耀控股股东及高管承诺半年内不出售股份3月18日,云顶新耀宣布,控股股东CBC集团及相关高管已向公司发出通知,他们自愿承诺在未来至少六个月内不会出售其持有的公司股份。公司执行董事兼首席执行官罗永庆表示,他们对公司的长期发展充满信心。此次股份禁售承诺将有助于稳定市场对云顶新耀的信心,为公司未来的发展创造良好环境。和讯竭力但不能证实上述内容的真实性、准确性和原创性,对此和讯不做任何保证和承诺。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202403181743108b42a05a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202403181743108b42a05a&s=b","is_publish_highlight":false,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.everestmedicines.com","stockEarnings":[{"period":"1week","weight":-0.0637},{"period":"1month","weight":0.0538},{"period":"3month","weight":0.1244},{"period":"6month","weight":-0.06},{"period":"1year","weight":0.4911},{"period":"ytd","weight":0.1244}],"compareEarnings":[{"period":"1week","weight":-0.0191},{"period":"1month","weight":-0.0149},{"period":"3month","weight":-0.0297},{"period":"6month","weight":-0.0712},{"period":"1year","weight":-0.1808},{"period":"ytd","weight":-0.0297}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"云顶新耀有限公司是一家主要从事疗法的特许、临床开发及商业化业务,以解决尚未满足的医疗需求。该公司一直专注于创新候选药物的研发。该公司已开发极具前景的临床阶段候选药物产品组合,覆盖肿瘤、免疫学、心肾疾病及感染性疾病。该公司主要在大中华及亚太区其他新兴市场提供产品与服务。","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":0.043978},{"month":2,"riseRate":0.25,"avgChangeRate":0.025861},{"month":3,"riseRate":0.25,"avgChangeRate":-0.030941},{"month":4,"riseRate":0,"avgChangeRate":-0.145301},{"month":5,"riseRate":0.666667,"avgChangeRate":0.018155},{"month":6,"riseRate":1,"avgChangeRate":0.412865},{"month":7,"riseRate":0,"avgChangeRate":-0.200039},{"month":8,"riseRate":0,"avgChangeRate":-0.206077},{"month":9,"riseRate":0.666667,"avgChangeRate":0.011102},{"month":10,"riseRate":0.333333,"avgChangeRate":-0.050127},{"month":11,"riseRate":0.5,"avgChangeRate":0.116383},{"month":12,"riseRate":0.75,"avgChangeRate":0.148847}],"exchange":"SEHK","name":"云顶新耀-B","nameEN":"EVEREST MED - B"},"APP":{"userAgent":"claudebot","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.22.3","shortVersion":"4.22.3","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"云顶新耀-B(01952)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供云顶新耀-B(01952)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"云顶新耀-B,01952,云顶新耀-B股票,云顶新耀-B股票老虎,云顶新耀-B股票老虎国际,云顶新耀-B行情,云顶新耀-B股票行情,云顶新耀-B股价,云顶新耀-B股市,云顶新耀-B股票价格,云顶新耀-B股票交易,云顶新耀-B股票购买,云顶新耀-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"云顶新耀-B(01952)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供云顶新耀-B(01952)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}